Ascelia Pharma: A delay. Fundamentals for Mangoral remain unchanged
Ascelia Pharma’s announcement of a three to six-month delay of the ongoing pivotal phase III SPARKLE study is not surprising given the circumstances with the ongoing covid-19 pandemic and its impact on clinical trials.
In our previous update, we estimated launch during 2022. The revised timeline has a marginal impact on our valuation as the DCF model is mainly impacted by the free cash flow in the final years of the forecast. Our risk-adjusted DCF valuation of the lead project Mangoral results in a value for Ascelia of SEK 52 per share, down from SEK 54 per share.
Read More
Vator Securities advises Xbrane Biopharma on 146 MSEK directed share issue
Vator Securities acted as Global Coordinator and Sole Bookrunner in connection with the transaction raising SEK 146million.
The Directed Share Issue was directed to selected Swedish and international institutional investors, among others, TIN Fonder, Swedbank Robur Ny Teknik and current shareholders Swedbank Robur Medica, STADA Arzneimittel and Serendipity Group among others.
Read More
Vator Securities advises NextCell Pharma on 25 MSEK Rights Issue
Vator Securities acts as Financial Advisor in connection with the transaction raising SEK 25 million.
NextCell is a cell therapy company with its leading drug candidate, ProTrans™, a treatment for type 1 diabetes, in a clinical phase II.
Read More
Projektledare med 4–5 års erfarenhet inom Corporate Finance till Vator Securities
Vator Securities växer och söker nu efter en projektledare med erfarenhet från Corporate Finance. Du erbjuds en utmanade och utvecklande tjänst i ett framgångsrikt bolag med högt driv och engagemang.
Du kommer att utgöra en viktig del av ett sammansvetsat team och få en unik möjlighet att utvecklas i takt med att bolaget växer ytterligare.
Read More
Swiss Nordic Bio 2020
Swiss Nordic Bio 2020 was held on 6 February in Zurich and was a collaboration between Vator Securities, the Embassy of Sweden, the Norwegian Embassy, Business Sweden and Business Finland.
Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet.
Here you will find the film from the event.
Read More
Junior Equity Analyst (Aktieanalytiker) inom Healthcare till Vator Securities
Som Junior Equity Analyst inom Healthcare kommer huvudsakliga arbetsuppgifter centrera kring förberedande arbete så som research, planering samt framtagandet av aktieanalyser som resurs till ansvarig analytiker.
Rollen inkluderar även deltagande på möten med publika bolag, för att få en större förståelse om en bransch och ett bolags strategiska inriktning, samt investerare och branschexperter.
Read More
IBD Junior Analyst – Corporate Finance till Vator Securities
Som junior analytiker kommer fokus ligga på att assistera dina kollegor vid framtagandet av företagspresentationer, arbeta med research, samt bistå med administration kring transaktioner och projekt.
Teamet består idag av 5 personer och kommer att utökas med ytterligare juniora talanger.
Read More
Vator Securities advises SciBase on 25 MSEK Rights Issue
Vator Securities acts as Financial Advisor in connection with the transaction raising SEK 25 million.
The capital raised in the rights issue will primarily be used to increase the market presence and penetration of SciBase in the US market where an FDA approval of Nevisense 3.0 is expected during the second quarter of 2020.
Read More